ÀüÀÌµÈ À¯¹æ¾ÏÀÇ Eribulin plus Gemcitabine ´ë Paclitaxel plus Gemcitabine ÈÇпä¹ýºñ±³
ÀÓ»óÁú¹®
|
ÀüÀÌµÈ À¯¹æ¾Ï ȯÀÚ¿¡°Ô Eribulin plus Gemcitabine (EG) ´ë Paclitaxel plus Gemcitabine (PG) Ç׾Ͽä¹ýÀ» Åõ¿©ÇÒ °æ¿ì º¸´Ù È¿°úÀûÀÎ Ç×¾ÏÁ¦´Â ¹«¾ùÀΰ¡¿ä?
|
±Ù°Å±â¹Ý´äº¯
|
EG ÈÇÐ ¿ä¹ýÀº ¹«ÁøÇà »ýÁ¸À²¸é¿¡¼ PG ÈÇÐ ¿ä¹ý°ú À¯»çÇÑ ÀÓ»óÀû ÀÌÁ¡À» º¸¿´À¸³ª ½Å°æµ¶¼ºÀº Àû¾úÀ½À» º¸°íÇÏ¿´½À´Ï´Ù.
|
¼ÁöÁ¤º¸
|
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer (2017), European journal of cancer,
2017 Oct ; 86( 5 ) :385-393, DOI: 10.1016/j.ejca.2017.10.002
|
Áúº´Æ¯¼º
|
ÀüÀÌµÈ À¯¹æ¾Ï (Human epidermal growth factor receptor 2 À½¼º )
|
ÁßÀç¹æ¹ý
|
Eribulin plus gemcitabine ´ë Paclitaxel plus gemcitabine ºñ±³
|
¿¬±¸¼³°è
|
ÀüÇâÀû ¹«ÀÛÀ§ ÀÓ»ó 2»ó ½ÃÇè´ëÁ¶±º ¿¬±¸
(Prospective randomized phase II, multicentre study)
|
¿¬±¸´ë»ó
|
Human epidermal growth factor receptor 2-negative ÀüÀÌµÈ À¯¹æ¾Ï ȯÀÚ 118¸í
|
Æò°¡ÁöÇ¥
|
Overall survival (OS)
Progression-free survival (PFS)
Toxicity
|
»ó¼¼¼³¸í
|
ÀÌ ¿¬±¸´Â ÀüÀÌµÈ À¯¹æ¾ÏȯÀÚ¿¡°Ô EG¿Í PG¸¦ ºñ±³ÇÏ´Â ÀüÇâÀû ¹«ÀÛÀ§ ÀÓ»ó 2 »ó¿¬±¸·Î ¼öÇàµÇ¾úÀ¸¸ç, ¾ç±ºÀÇ 6 °³¿ù PFS´Â EG 72 %, PG 73 %¿´´Ù (P = 0.457). EG ÈÇÐ ¿ä¹ýÀº ¹«ÁøÇà »ýÁ¸À²¸é¿¡¼ PG ÈÇÐ ¿ä¹ý°ú À¯»çÇÑ ÀÓ»óÀû ÀÌÁ¡À» º¸¿´À¸³ª ½Å°æµ¶¼ºÀº Àû¾úÀ½À» º¸°íÇÏ¿´´Ù
|
±Ù°Å¼öÁØ
|
Moderate
|
ÀÛ¼ºÀÚ
|
ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ(MedRIC)
Copyright © 2015 Medical Research Information Center (MedRIC) Editors
|